Finally, HM0539 was demonstrated to be a promising anti-inflammatory drug, at least in part, by its decreased levels of the TLR4-MyD88 axis and of the downstream MyD88-dependent activated NF-κB signaling, and therefore it may be evaluated as a viable treatment alternative for IBD. This evidence concerns the gene TLR4 and irritable bowel syndrome.